Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease with 0-2 Risk Factors
Research committees
Treatment
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
2018
2017
PMid: PMID28082441 | PMC number: PMC5374291
2015
PMid: PMID25897153 | PMC number: PMC4451176
PMid: PMID26343802 | PMC number: PMC4881845
2014
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience
PMid: PMID24567515; PMC4433526
2013
PMid: PMID23182984 | PMC number: PMC3574267
PMid: PMID23182987 | PMC number: PMC3574266
Plasma Epstein-Barr viral DNA as a marker of tumor response in Hodgkin lymphoma
PMid: PMID23386127 | PMC number: PMC3643756
PMid: PMID23356491 | PMC number: PMC3906856
2012
Tumor-associated macrophages predict inferior outcomes in locally advanced and advanced stage classical Hodgkins lymphoma - a correlative study from the E2496 intergroup trial http://www.abstracts2view.com/uscap12/view.php?nu=USCAP12L_1568
PMid: PMID22948049 | PMC number: PMC3476539
2011
Patterns of failure in patients with stage I/II bulky mediastinal hodgkins lymphoma (HL) treated with ABVD + radiotherapy or the Stanford V regimen in the randomized phase III North American Intergroup trial: E2496
A gene expression signature in diagnostic formalin fixed paraffin embedded tissue predicts overall survival in locally advanced and advanced stage classical hodgkin lymphoma - a correlative study from the E2496 intergroup trial
2010
A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin's lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)